Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
54 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
- Westmead Hospital
Westmead, New South Wales, Australia
- Hôpital Erasme
Brussels, Brussels Capital, Belgium
- Uz Leuven - Campus Gasthuisberg - Pneumologie
Leuven, Vlaams Brabant, Belgium
- University of Calgary
Calgary, Alberta, Canada
- St Joseph'S Healthcare Hamilton Research
Hamilton, Ontario, Canada
- University Institute of Cardiology and Respirology of Quebec
Québec, Canada
- Hôpital Louis Pradel
Bron, Auvergne-Rhône-Alpes, France
- Chu Pontchaillou
Rennes, Brittany Region, France
- Thoraxklinik Heidelberg Ggmbh Am Universitätsklinikum Heidelberg
Heidelberg, Baden-Wurttemberg, Germany
- Asklepios Fachkliniken Muenchen-Gauting
Muenchen-Gauting, Bavaria, Germany
- Ruhrlandklinik Westdeutsches Lungenzentrum
Essen, North Rhine-Westphalia, Germany
- Attikon University Hospital
Athens, Greece
- St. Vincent'S University Hospital
Dublin, Ireland
- Fondazione Irccs Policlinico San Matteo
Pavia, Lombardy, Italy
- Hokkaido University Hospital
Sapporo, Hokkaidô, Japan
- Kanagawa Cardiovascular and Respiratory Center
Yokohama, Kanagawa, Japan
- Tohoku University Hospital - Respiratory Tract Medicine
Sendai, Miyagi, Japan
- National Hospital Organization Kinki-Chuo Chest Medical Center
Sakai, Osaka, Japan
- Kyorin University Hospital
Mitaka, Tokyo, Japan
- Chiba University Hospital - Respiratory Medicine
Chiba, Japan
- Kumamoto University Hospital
Kumamoto, Japan
- Aichi Medical University Hospital
Nagakute, Japan
- Saitama Red Cross Hospital
Saitama, Japan
- St Antonius Hospital
Nieuwegein, Utrecht, Netherlands
- Instytut Gruzlicy I Chorob Pluc
Warsaw, Masovian Voivodeship, Poland
- Hospital Pulido Valente
Lisbon, Portugal
- Hospital São João
Porto, Portugal
- Institutul de Pneumoftiziologie "marius Nasta"
Bucharest, Romania
- Asan Medical Center
Seoul, South Korea
- Samsung Medical Center
Seoul, South Korea
- Seoul National University Hospital
Seoul, South Korea
- Severance Hospital - Yonsei University Health System - Pulmonary
Seoul, South Korea
- Hospital Universitario de Bellvitge
Barcelona, Catalonia, Spain
- Ege University Hospital - Department of Pulmonology
Bornova, İzmir, Turkey (Türkiye)
- Health Sciences University Gulhane Training and Research Hospital
Ankara, Turkey (Türkiye)
- Yedikule Chest Disease and Surgery Training and Research Hospital
Istanbul, Turkey (Türkiye)
- Royal Brompton and Harefield Nhs Foundation Trust
London, United Kingdom
- University of Arkansas for Medical Services
Little Rock, Arkansas, United States
- Ucla David Geffen School of Medicine
Los Angeles, California, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 19 May 2021
- Primary completion
- 30 Nov 2023
- Completion
- 30 May 2027
- Last update posted
- 7 Aug 2025
- Registered enrollment
- 164
- Registry id
- NCT04544293
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.